Labiotech.eu

elypta renal cell carcinoma kidney cancer

News and Trends 28 Oct 2022

Rila Therapeutics exits stealth mode to address renal fibrosis

Rila Therapeutics, a biotherapeutics company focused on addressing the critical unmet medical needs to treat renal fibrosis, has emerged from stealth mode. Rila Therapeutics has identified a promising, first-in-class allosteric small molecule targeting HIPK2 to inhibit kidney fibrosis. The breakthrough discovery aiming to advance the treatment of renal disease was developed in collaboration with Mount […]

October 28, 2022 - 3 minutesmins - By Jim Cornall

More News! 28 Oct 2022

‘Dark matter’ creates a whole new level of cancer gene activity in tumors, researchers say

A whole new level of control of cancer gene activity within tumors, has been described by researchers as ‘dark matter’. It was recently discovered and published in two major studies at the same time in Nature that cancers can evolve to become more aggressive without relying on DNA mutations. Testing cancers for just the DNA […]

October 28, 2022 - 6 minutesmins - By Liza Laws

Persephone Bisociences Microbiome health

Startup Scout 28 Oct 2022

Persephone Biosciences studies the microbiome in baby poop

Disruption in the gut microbiome is linked to a wide range of health problems in newborn babies and patients with cancer. Persephone Biosciences is studying stool samples from these populations to devise bacterial treatments that improve gut health. Research into the gut microbiome has advanced a long way in the last decades. One major boost […]

October 28, 2022 - 6 minutesmins - By Jonathan Smith

AKT inhibitor ipatasertib shows signs of effectiveness in patient trial

News and Trends 28 Oct 2022

AKT inhibitor shows signs of effectiveness in patient trial

In a trial matching new treatments to cancer patients based on the genetic make-up of their tumors, 22% of the patients treated with the AKT inhibitor drug ipatasertib had their tumors shrink. This included patients with breast cancer and endometrial cancer as well as two rarer forms – anal and salivary gland. In the majority […]

October 28, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Oct 2022

Beyond Biotech podcast 20: BioWin, eTherapeutics, CMT Research Foundation

This week, we have three interviews, and four guests. We chatted with Keith Fargo, chief scientific officer at the CMT Research Foundation; François Colery, head of the Talent Now initiative and Sylvie Ponchaut, managing director, from BioWin; and e-therapeutics’ CEO, Ali Mortazavi. We also have our weekly contribution from global commercial real estate services company […]

October 28, 2022

News and Trends 28 Oct 2022

Researchers identify gene alterations that may affect response to brain cancer treatment

Spanish researchers have identified a range of genetic alterations in glioma brain cancers that will help them to understand how different mutations in one particular gene interact with other gene alterations and which ones are more susceptible to targeted treatments in adults. Presenting results from the largest group of glioma patients to date, Karisa Schreck […]

October 28, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 28 Oct 2022

Cali Biosciences publishes ropivacaine results

Cali Biosciences Co., Ltd. has announced two milestones for CPL-01, its long-acting ropivacaine for post-operative analgesia and opioid elimination/reduction. The company saw the publication of CPL-01, an Investigational Long-Acting Ropivacaine, Exhibits Extended-Release Properties after Mini-abdominoplasty in the Japan Journal of Medicine. It also gave a presentation of preclinical data at the American Association of Pharmaceutical […]

October 28, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 26 Oct 2022

Singapore approves gas fermentation-powered protein

A food ingredient developed by the Finnish startup Solar Foods has earned its first market approval in Singapore. The product is brewed using microorganisms fed with carbon dioxide and electricity — a more sustainable alternative to conventional animal protein. Increasing numbers of fermentation-derived food products are reaching the market, including ingredients developed by Motif FoodWorks, […]

October 26, 2022 - 3 minutesmins - By Jonathan Smith

More News! 26 Oct 2022

Study shows ability to develop and apply targeted treatment in head and neck cancers

A joint study looked at the development identification of specific markers to improve risk assessment of patients with difficult to treat head and neck tumors. Malignant tumors in these areas are very heterogeneous and have a lack of prognostic markers – a significant impediment to personalized treatment. The joint study by MedUni Vienna and the […]

October 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Oct 2022

First patient dosed in trial to assess predictive performance of immuno-oncology therapy

The first patient has been dosed at the Macquarie University Hospital in Sydney as part of a clinical trial to evaluate whether a drug can predict patient response to immuno-oncology therapy targeting a number of solid tumor types. ImaginAb Inc. is a biotech company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and next generation […]

October 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Oct 2022

Partnership between Paradigm4 and Alnylam accelerates drug target discovery

New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam. Paradigm4’s REVEAL integrative analytics platform enables extraordinary pace and productivity Alnylam Pharmaceuticals to access the targets for its therapeutics pipeline at a very fast pace. Using the cloud-based scientific analytics […]

October 26, 2022 - 3 minutesmins - By Liza Laws

More News! 26 Oct 2022

Neuraxpharm to commercialize device giving early warning of epileptic seizures

A wearable medical device that can give an early warning of an epileptic seizure has been developed by medical device startup, mjn-neuro. Central nervous system (CNS) specialist Neuraxpharm Group entered the digital health market by signing a commercialization agreement with the developer for mjn-SERAS with exclusivity in Europe. With this agreement, Neuraxpharm increases its end-to-end […]

October 26, 2022 - 4 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Rila Therapeutics exits stealth mode to address renal fibrosis

‘Dark matter’ creates a whole new level of cancer gene activity in tumors, researchers say

Persephone Biosciences studies the microbiome in baby poop

AKT inhibitor shows signs of effectiveness in patient trial

Beyond Biotech podcast 20: BioWin, eTherapeutics, CMT Research Foundation

Researchers identify gene alterations that may affect response to brain cancer treatment

Cali Biosciences publishes ropivacaine results

Singapore approves gas fermentation-powered protein

Study shows ability to develop and apply targeted treatment in head and neck cancers

First patient dosed in trial to assess predictive performance of immuno-oncology therapy

Partnership between Paradigm4 and Alnylam accelerates drug target discovery

Neuraxpharm to commercialize device giving early warning of epileptic seizures

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!